Literature DB >> 18704351

[Guidelines for the management of osteoporosis].

J Pfeilschifter1.   

Abstract

Treatment of osteoporosis aims to reduce osteoporotic fractures and to minimize fracture-related pain and functional impairment. Components of non-drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of vitamin D and an individual assessment of drugs known to increase falls or osteoporosis. Bisphosphonates, raloxifene, strontium ranelate and parathyroid hormone have been shown to reduce osteoporotic fractures in postmenopausal women. Alendronate, risedronate and parathyroid hormone are also licensed for the treatment of male osteoporosis. One of the still open questions is the optimal duration of pharmacological treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704351     DOI: 10.1007/s00108-008-2115-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  4 in total

1.  Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.

Authors:  Ann Cranney; Gordon Guyatt; Lauren Griffith; George Wells; Peter Tugwell; Clifford Rosen
Journal:  Endocr Rev       Date:  2002-08       Impact factor: 19.871

Review 2.  Diet, nutrition and the prevention of osteoporosis.

Authors:  A Prentice
Journal:  Public Health Nutr       Date:  2004-02       Impact factor: 4.022

Review 3.  Therapy of osteoporosis with calcium and vitamin D.

Authors:  Bess Dawson-Hughes; Heike A Bischoff-Ferrari
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

Review 4.  Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?

Authors:  E Seeman
Journal:  Bone       Date:  2007-06-26       Impact factor: 4.398

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.